Reduction of myeloperoxidase activity by melatonin and pycnogenol may contribute to their blood pressure lowering effect

Hypertension

Volumn 56, Issue 3, 2010, Pages

  Van Der Zwan, Leonard P ^a   Scheffer, Peter G ^a   Teerlink, Tom ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROGEN PEROXIDE; MELATONIN; MYELOPEROXIDASE; NITRIC OXIDE; PYCNOGENOL; REACTIVE OXYGEN METABOLITE;

ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BIOSYNTHESIS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME REPRESSION; HUMAN; IMMUNE RESPONSE; LETTER; MICROVASCULATURE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL;

ANIMALS; BLOOD PRESSURE; FLAVONOIDS; MELATONIN; PEROXIDASE; RATS; RATS, INBRED SHR;

EID: 77955981807     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.110.158170     Document Type: Letter

References (5)

1. Rezzani R, Porteri E, De Ciuceis C, Bonomini F, Rodella LF, Paiardi S, Boari GEM, Platto C, Pilu A, Avanzi D, Rizzoni D, Agabiti Rosei E. Effects of melatonin and pycnogenol on small artery structure and function in spontaneously hypertensive rats. Hypertension. 2010;55:1373-1380.
2. Ferri C, Grassi D. Antioxidants and beneficial microvascular effects: is this the remedy? Hypertension. 2010;55:1310-1311.
3. Schindhelm RK, Van Der Zwan LP, Teerlink T, Scheffer PG. Myeloper-oxidase: a useful biomarker for cardiovascular disease risk stratification? Clin Chem. 2009;55:1462-1470.
4. Van Der Zwan LP, Scheffer PG, Dekker JM, Stehouwer CDA, Heine RJ, Teerlink T. Hyperglycemia and oxidative stress strengthen the association between myeloperoxidase and blood pressure. Hypertension. 2010;55: 1366-1372.
5. Galijasevic S, Abdulhamid I, Abu-Soud HM. Melatonin is a potent inhibitor for myeloperoxidase. Biochemistry. 2008;47:2668-2677.